OBJECTIVE: To assess the continuity of care and outcome of pediatric HIV prevention, testing, and treatment services, focusing on early infant diagnosis with DNA polymerase chain reaction (PCR). DESIGN: A retrospective observational cohort. METHODS: Maternal HIV antibody, infant HIV DNA PCR test results, and outcome data from HIV-infected infants from the prevention of mother-to-child transmission, early infant diagnosis, and pediatric HIV treatment programs operating in Lilongwe, Malawi, between 2004 and 2008 were collected, merged, and analyzed. RESULTS: Of the 14,669 pregnant women who tested HIV antibody positive, 7875 infants (53.7%) received HIV DNA PCR testing. One thousand eighty-four infants (13.8%) were HIV infected. Three hundred twenty (29.5%) children enrolled into pediatric HIV care, with 202 (63.1%) at the Baylor Center of Excellence. Among these, antiretroviral therapy was initiated on 110 infants (54.5%) whose median age was 9.1 months (interquartile range, 5.4-13.8) and a median of 2.5 months (interquartile range, 1.4-5.2) after HIV clinic registration. Sixty-nine HIV-infected infants (34.2%) died or were lost by December 2008. Initiation of antiretroviral therapy increased the likelihood of survival 7-fold (odds ratio, 7.1; 95% confidence interval, 3.68 to 13.70). CONCLUSIONS: Separate programs for maternal and infant HIV prevention and care services demonstrated high attrition rates of HIV-exposed and HIV-infected infants, elevated levels of mother-to-child transmission, late infant diagnosis, delayed pediatric antiretroviral therapy initiation, and high HIV-infected infant mortality. Antiretroviral therapy increased HIV-infected infant survival, emphasizing the urgent need for improved service coordination and strategies that increase access to infant HIV diagnosis, improve patient retention, and reduce antiretroviral therapy initiation delays.
OBJECTIVE: To assess the continuity of care and outcome of pediatric HIV prevention, testing, and treatment services, focusing on early infant diagnosis with DNA polymerase chain reaction (PCR). DESIGN: A retrospective observational cohort. METHODS:Maternal HIV antibody, infant HIV DNA PCR test results, and outcome data from HIV-infectedinfants from the prevention of mother-to-child transmission, early infant diagnosis, and pediatric HIV treatment programs operating in Lilongwe, Malawi, between 2004 and 2008 were collected, merged, and analyzed. RESULTS: Of the 14,669 pregnant women who tested HIV antibody positive, 7875 infants (53.7%) received HIV DNA PCR testing. One thousand eighty-four infants (13.8%) were HIV infected. Three hundred twenty (29.5%) children enrolled into pediatric HIV care, with 202 (63.1%) at the Baylor Center of Excellence. Among these, antiretroviral therapy was initiated on 110 infants (54.5%) whose median age was 9.1 months (interquartile range, 5.4-13.8) and a median of 2.5 months (interquartile range, 1.4-5.2) after HIV clinic registration. Sixty-nine HIV-infectedinfants (34.2%) died or were lost by December 2008. Initiation of antiretroviral therapy increased the likelihood of survival 7-fold (odds ratio, 7.1; 95% confidence interval, 3.68 to 13.70). CONCLUSIONS: Separate programs for maternal and infant HIV prevention and care services demonstrated high attrition rates of HIV-exposed and HIV-infectedinfants, elevated levels of mother-to-child transmission, late infant diagnosis, delayed pediatric antiretroviral therapy initiation, and high HIV-infectedinfant mortality. Antiretroviral therapy increased HIV-infectedinfant survival, emphasizing the urgent need for improved service coordination and strategies that increase access to infant HIV diagnosis, improve patient retention, and reduce antiretroviral therapy initiation delays.
Authors: M Manzi; R Zachariah; R Teck; L Buhendwa; J Kazima; E Bakali; P Firmenich; P Humblet Journal: Trop Med Int Health Date: 2005-12 Impact factor: 2.622
Authors: Simon Makombe; Edwin Libamba; Eustice Mhango; Olga de Ascurra Teck; John Aberle-Grasse; Mindy Hochgesang; Erik J Schouten; Anthony D Harries Journal: Trans R Soc Trop Med Hyg Date: 2006-01-26 Impact factor: 2.184
Authors: Elizabeth M Stringer; Didier K Ekouevi; David Coetzee; Pius M Tih; Tracy L Creek; Kathryn Stinson; Mark J Giganti; Thomas K Welty; Namwinga Chintu; Benjamin H Chi; Catherine M Wilfert; Nathan Shaffer; Francois Dabis; Jeffrey S A Stringer Journal: JAMA Date: 2010-07-21 Impact factor: 56.272
Authors: Katherine Luzuriaga; Margaret McManus; Lynne Mofenson; Paula Britto; Bobbie Graham; John L Sullivan Journal: N Engl J Med Date: 2004-06-10 Impact factor: 91.245
Authors: Joséphine Braun; Jean-Christophe Plantier; Marie-France Hellot; Edouard Tuaillon; Marie Gueudin; Florence Damond; Anders Malmsten; Gary E Corrigan; François Simon Journal: AIDS Date: 2003-02-14 Impact factor: 4.177
Authors: Rony Zachariah; Anthony David Harries; Marcel Manzi; Patrick Gomani; Roger Teck; Mit Phillips; Peter Firmenich Journal: PLoS One Date: 2006-12-27 Impact factor: 3.240
Authors: James T Pfeiffer; Manuel Napúa; Bradley H Wagenaar; Falume Chale; Roxanne Hoek; Mark Micek; João Manuel; Cathy Michel; Jessica Greenberg Cowan; James F Cowan; Sarah Gimbel; Kenneth Sherr; Stephen Gloyd; Rachel R Chapman Journal: J Acquir Immune Defic Syndr Date: 2017-11-01 Impact factor: 3.731
Authors: Eric D McCollum; Derek C Johnson; Charles S Chasela; Linias D Siwande; Peter N Kazembe; Dan Olson; Irving Hoffman; Charles van der Horst; Mina C Hosseinipour Journal: J Acquir Immune Defic Syndr Date: 2012-08-01 Impact factor: 3.731
Authors: Alison C Roxby; Jennifer A Unger; Jennifer A Slyker; John Kinuthia; Andrew Lewis; Grace John-Stewart; Judd L Walson Journal: Curr HIV/AIDS Rep Date: 2014-06 Impact factor: 5.071
Authors: Muktar H Aliyu; Meridith Blevins; Karen M Megazzini; Carolyn M Audet; Julie Dunlap; Ibrahim S Sodangi; Usman I Gebi; Bryan E Shepherd; C William Wester; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731
Authors: Madalitso Maliwichi; Nora E Rosenberg; Rebekah Macfie; Dan Olson; Irving Hoffman; Charles M van der Horst; Peter N Kazembe; Mina C Hosseinipour; Eric D McCollum Journal: Trop Med Int Health Date: 2014-04-23 Impact factor: 2.622
Authors: Charles Kiyaga; Hakim Sendagire; Eleanor Joseph; Jeff Grosz; Ian McConnell; Vijay Narayan; Godfrey Esiru; Peter Elyanu; Zainab Akol; Wilford Kirungi; Joshua Musinguzi; Alex Opio Journal: J Public Health Policy Date: 2015-03-26 Impact factor: 2.222
Authors: Philip J Ciampa; José A Tique; Nilton Jumá; Mohsin Sidat; Troy D Moon; Russell L Rothman; Sten H Vermund Journal: J Acquir Immune Defic Syndr Date: 2012-06-01 Impact factor: 3.731
Authors: Eric D McCollum; Geoffrey A Preidis; Madalitso Maliwichi; Dan Olson; L Madeline McCrary; Peter N Kazembe; Charles van der Horst; Irving Hoffman; Mina C Hosseinipour Journal: J Acquir Immune Defic Syndr Date: 2014-05-01 Impact factor: 3.731
Authors: Lydia Feinstein; Andrew Edmonds; Jean Lambert Chalachala; Vitus Okitolonda; Jean Lusiama; Annelies Van Rie; Benjamin H Chi; Stephen R Cole; Frieda Behets Journal: AIDS Date: 2014-07 Impact factor: 4.177